Rapid risk assessment: Public health risks related to communicable diseases during the hajj 2019, Saudi Arabia, 9–14 August 2019
In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.
- Food- and waterborne diseases
- Hepatitis A
- Hepatitis B
- Mass gathering
- Meningococcal disease
- Middle East respiratory syndrome coronavirus
- Public health threat
- Saudi Arabia
- Travellers' health
- Vaccine preventable diseases
- Vector-borne disease
Hepatitis B - Annual Epidemiological Report for 2017
In 2017, 30 EU/EEA Member States reported 26 907 cases of hepatitis B virus (HBV) infection. Excluding the five countries that only reported acute cases, the number of cases, 26 262, corresponds to a crude rate of 6.7 cases per 100 000 population.
Communicable Disease Threats Report, 19-25 May 2019, Week 21
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period from 19-25 May 2019 and includes updates on rat hepatitis B, dengue, Ebola virus disease, influenza, Legionnaires' disease and P. vivax malaria.
Hepatitis C - Annual Epidemiological Report for 2017
In 2017, 31 273 cases of hepatitis C were reported in 29 EU/EEA Member States. Excluding countries that only reported acute cases, 31 178 cases corresponds to a crude rate of 7.3 cases per 100 000 population.
Hepatitis A - Annual Epidemiological Report for 2016
In 2016, 29 EU/EEA countries reported 12 502 cases of hepatitis A, of which 12 429 (99.4%) were confirmed.
Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA
The scope of this project was to provide an overview of different effective testing strategies for hepatitis B and C and their outcomes in the EU/EEA, covering all relevant population groups and settings.
Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA
The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance
Public health guidance on HIV, hepatitis B and C testing in the EU/EEA
This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.
Hepatitis B and C epidemiology in selected population groups in the EU/EEA
The findings presented in this report will be part of the process of developing a European guidance for HBV and HCV testing and may provide support EU/EEA countries in the development of national guidelines and in the design and scale-up of testing interventions.
Public health guidance on prevention and control of blood-borne viruses in prison settings
This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.